title: [Cabergoline in hyperprolactinemia and valvular heart disease].
abstract: BACKGROUND
  High-dose cabergoline therapy has been related to cardiac valve regurgitation in patients with Parkinson's disease.
  
  
  OBJECTIVE
  To perform a systematic analysis of reports on low-dose cabergoline treatment in hyperprolactinemia and its effect on the cardiac valves.
  
  
  RESULTS
  None of the seven reports analyzed, including 463 patients in total, found clinically significant valve regurgitation. Only one report found moderate tricuspid valve regurgitation, and other two reports found mild tricuspid valve regurgitation. An increase in the mitral tenting area was documented in only one of two reports. Valve thickening and calcifications were found in only one study.
  
  
  CONCLUSIONS
  Cabergoline seems to be safe at the doses employed in hyperprolactinemic patients. There is a higher prevalence of tricuspid regurgitation, detected by systematic echocardiography, but this abnormality is asymptomatic. Although prospective longitudinal studies are needed, vigilance of these patients is recommended, especially those treated with high-dose cabergoline.
authors: Servicio de Endocrinología y Nutrición, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, España. marcos.lahera@salud.madrid.org
authors: Marcos Lahera
authors: ML
authors: Vargas
authors: Carlos Escobar
authors: CE
authors: Cervantes
authors: Carmen Alameda
authors: CA
authors: Hernando
authors: César Varela
authors: CV
authors: Da Costa
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077465:Cabergoline; D016022:Case-Control Studies; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism; D015995:Prevalence; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000188:drug therapy / Q000378:metabolism; D014463:Ultrasonography
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline